Form 8-K - Current report:
SEC Accession No. 0001437749-24-024658
Filing Date
2024-08-05
Accepted
2024-08-05 16:33:18
Documents
15
Period of Report
2024-08-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K krbp20240801_8k.htm   iXBRL 8-K 31834
2 EXHIBIT 10.1 ex_707309.htm EX-10.1 143408
  Complete submission text file 0001437749-24-024658.txt   345317

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA krbp-20240801.xsd EX-101.SCH 3408
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE krbp-20240801_def.xml EX-101.DEF 11818
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE krbp-20240801_lab.xml EX-101.LAB 15883
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE krbp-20240801_pre.xml EX-101.PRE 12033
17 EXTRACTED XBRL INSTANCE DOCUMENT krbp20240801_8k_htm.xml XML 2932
Mailing Address 7707 FANNIN ST. SUITE 140 HOUSTON TX 77054
Business Address 7707 FANNIN ST. SUITE 140 HOUSTON TX 77054 832-968-4888
Kiromic Biopharma, Inc. (Filer) CIK: 0001792581 (see all company filings)

EIN.: 464762913 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39619 | Film No.: 241175303
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)